| Name | Trifluoperazine dihydrochloride |
| Description | Trifluoperazine dihydrochloride (SKF5019) is a potent dopamine D2 receptor inhibitor used as an antipsychotic and an antiemetic. |
| In vitro | Trifluoperazine binds to α1A- and α1B-adrenoceptor with Ki value of 27.6 nM and 19.2 nM, respectively, with α1B/α1A ratio of 0.7. [2] Trifluoperazine inhibits Mycobacterium tuberculosis (Mtb) with MICs of 7.6 μg/mL. [3] Trifluoperazine (< 14.78 mM) suppresses the activities of the mouse splenic NK cell cytotoxicity and the effector-target cell conjugation in a dose dependent manner. Trifluoperazine suppresses interferon-alpha or interleukin-2 induced augmentation of the cytolytic activity of NK cells. [4] Trifluoperazine inhibits the gene expression of voltage-dependent potassium channel Kv2.1 from human brain (hKv2.1). [5] |
| In vivo | Trifluoperazine dose dependently decreases avoidance responses and increases response failures in rats where behavior is maintained under a discrete-trial avoidance. [6] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 71.43 mg/mL (148.68 mM), Sonication is recommended.
DMSO : 247.5 mg/mL (515.16 mM), Sonication is recommended.
Ethanol : 89 mg/mL (185.25 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (6.87 mM), Sonication is recommended.
|
| Keywords | Trifluoperazine dihydrochloride | Trifluoperazine | SKF-5019 | SKF 5019 | schizophrenia | P-gp (P-glycoprotein) | P-gp | Pgp | P-glycoprotein | NUPR1 | Multidrug resistance protein 1 | morphogenesis | MDR1 | Inhibitor | inhibit | InfluenzaVirus | Influenza Virus | DopamineReceptor | Dopamine Receptor | Dopamine | D2 | Cluster of differentiation 243 | CD243 | CaMK | Calmodulin-dependent protein kinases | Calmodulin-dependent kinases | Beta Receptor | Autophagy | antipsychotic | anticancer | AdrenergicReceptor | Adrenergic Receptor | ABCB1 |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Hydroxychloroquine | Enzalutamide | Paeonol | Naringin | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Kinase Inhibitor Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
